Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
about
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumorAssessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinomaAxitinib plasma pharmacokinetics and ethnic differences.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.Racial disparity in metastatic renal cell cancer: the pharmaco-anthropology of sunitinib.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.
P2860
Q31102468-93618194-8F03-4D2E-A4FA-3C50B03090CEQ33425872-631A002B-8274-4B22-B10E-1762FD521BD6Q33437427-17B9B1A6-A703-4A4A-8E18-968C64306E35Q36093104-9B118D48-890F-4A13-A4BA-222A46AF715FQ38348548-84E13C09-2682-4569-AE7F-B455F4784EABQ38799848-01AAB10A-2982-4D11-B92B-2021984FB2D4Q40732067-89349CF4-1156-4019-9FED-A35E5D958C33Q47613533-1F58A3C0-7A6C-4D6C-BE85-8A240C3B5259Q48306032-0ADD8D47-6394-4938-9841-C17B62DD211FQ49997360-4D26CFA5-658A-4DA0-A577-4832C6E352B7Q50600192-4A8658F4-3E6A-49EE-870B-4FC5E2B85EF8Q53581485-686F5CE6-228D-4705-9EE1-D238D2A3B975Q53669584-E2E4F16E-36B7-4285-B4F2-95AA7D59E5A7Q54119194-608A2B93-DF46-44B5-8CC5-CF2347E48297
P2860
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@ast
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@en
type
label
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@ast
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@en
prefLabel
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@ast
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@en
P2093
P2860
P356
P1476
Sunitinib in metastatic renal ...... lysis for safety and efficacy.
@en
P2093
Christina Ng
Jinyu Yuan
John W-C Chang
Paul Mainwaring
Philip Kwong
Se-Hoon Lee
Susan Pitman Lowenthal
Virote Sriuranpong
Yung-Jue Bang
P2860
P304
P356
10.1111/AJCO.12163
P577
2014-02-27T00:00:00Z